宁波美诺华药业股份有限公司 关于2021年股票期权与限制性股票激励计划预留授予 第二个行权期自主行权结果暨股份变动公告

Core Points - The company has announced the second exercise period for its 2021 stock option and restricted stock incentive plan, allowing for the exercise of 738,491 shares from December 25, 2024, to November 24, 2025, with 278,530 shares exercised to date, representing 37.72% of the total available for this period [1][18][19] Decision-Making Process and Disclosure - On November 18, 2021, the company held its fourth board meeting, approving several proposals related to the stock option and restricted stock incentive plan, with independent directors expressing their agreement [1][2][3] - The company also held a temporary shareholders' meeting on December 6, 2021, where over two-thirds of the voting rights approved the same proposals [3] Adjustments and Approvals - On August 15, 2022, the company adjusted the number and price of the stock options and restricted stocks in the incentive plan [4] - The company completed the registration of 1,564,662 stock options on November 25, 2022 [6] Exercise and Trading Arrangements - The stock options will be exercised through a self-exercise method, with shares reaching the accounts of the incentive participants on the first trading day after the exercise date [18] - The total number of shares exercised as of November 24, 2025, is 278,530, with the total funds raised amounting to 6,328,201.60 yuan [19] Impact on Financial Reports - The exercise of these stock options is not expected to have a significant impact on the company's financial condition or operating results [19]